Portal de investigación
PIER trial: Neoadjuvant therapy with panitumumab (P) and mFOLFOX-6 in an enriched population of patients with T3 rectal adenocarcinoma of the middle third with clear mesorectal fascia.
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Fernandez-Martos, Carlos
- Ayuso, Juan
- Capdevila, Jaume
- Gallego, Javier
- Losa, Ferran
- Maas, Monique
- Maurel, Joan
- Pericay, Carles
- Salas, Nuria Rodriguez
- Safont, Maria Jose
- Tobena, Maria
- Valladares, Manuel
- Vera, Ruth
Grupos
Abstract
Abstract no disponible
Datos de la publicación
- ISSN/ISSNe:
- 0732-183X, 1527-7755
- Tipo:
- Meeting Abstract
- Páginas:
- -
- Factor de Impacto:
- 11,754 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
JOURNAL OF CLINICAL ONCOLOGY LIPPINCOTT WILLIAMS & WILKINS
Documentos
- No hay documentos
Filiaciones
Filiaciones no disponibles
Campos de Estudio
Cita
Fernandez,C,Aparicio,J,Ayuso,J,Capdevila,J,Gallego,J,Losa,F,Maas,M et al. PIER trial: Neoadjuvant therapy with panitumumab (P) and mFOLFOX-6 in an enriched population of patients with T3 rectal adenocarcinoma of the middle third with clear mesorectal fascia. Gastrointestinal Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO). 2018. San Francisco-CA. TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103:LIPPINCOTT WILLIAMS & WILKINS. 2018.